联环药业(600513.SH)：公司盐酸林可霉素注射液通过仿制药质量和疗效一致性评价

Core Viewpoint - The announcement highlights that the company's subsidiary, Changle Pharmaceutical, has successfully passed the consistency evaluation for the quality and efficacy of Lincomycin Hydrochloride Injection, indicating a significant milestone in its product development and market potential [1] Group 1: Product Development - Changle Pharmaceutical's Lincomycin Hydrochloride Injection (specification: 2ml:0.6g) is classified as a lincosamide antibiotic, suitable for treating respiratory infections, skin and soft tissue infections, and bone and joint infections caused by sensitive bacteria [1] - In 2025, Changle Pharmaceutical received two production approvals for its products, reflecting its ongoing commitment to expanding its pharmaceutical offerings [1] Group 2: Financial Performance - The research and development investment for the consistency evaluation of Lincomycin Hydrochloride Injection amounted to approximately 2.328 million yuan [1] - In 2024, the domestic sales revenue for Lincomycin Hydrochloride Injection in sample hospitals reached 10.8176 million yuan, indicating a strong market presence and demand for the product [1]